Bisphosphonates
Antiresorptive pharmacology — mechanism, agents, osteoporosis & bone disease
Past RGUHS + DNB + MPMSU + MUHS · 27
RGUHSSep '25
MUHSWinter '25
DNBMay '24
MPMSUJun '23
DNBOct '23
RGUHSNov '22
RGUHSMay '22
MPMSU2022
RGUHSJul '21
MUHSSummer '21
MUHSSummer '21
MPMSUMay '19
MPMSU2019
MUHSWinter '19
MUHSSummer '19
RGUHSNov '18
MPMSU2017
MUHSSummer '17 Suppl
DNBDec '14
MPMSU2013
RGUHSMay '11
MPMSU2011
DNBDec '11
RGUHSOct '10
MPMSU2009
MPMSU2008
RGUHSApr '07
Introduction
- Definition — Synthetic, non-hydrolysable analogues of inorganic pyrophosphate in which the central O of the P–O–P backbone is replaced by carbon, giving a stable P–C–P ('geminal') structure.
- Class identity — The most potent and most widely used antiresorptive drugs; selectively inhibit osteoclast-mediated bone resorption.
- Anti-catabolic, not anabolic — Slow bone loss rather than build bone — BMD rises over the first ~12–18 months (filling of the remodeling space) then plateaus.
- Core uses — First-line for osteoporosis (postmenopausal, male, glucocorticoid-induced), Paget disease, hypercalcaemia of malignancy, and osteolytic metastases / multiple myeloma.
Continue reading
Bisphosphonates
PharmaNotes Pro · LAQ
Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.